Key Points: We analyzed a nationwide epidemiologic cohort including approximately 4,000,000 individuals. We found a potential association of inflammatory bowel disease with a greater risk of developing IgA nephropathy. Background: There have been scarce epidemiologic data on the relationship between inflammatory bowel disease and the incidence of IgA nephropathy. In this study, we assessed whether inflammatory bowel disease was associated with a higher risk of developing IgA nephropathy using a large-scale epidemiologic cohort. Methods: We retrospectively analyzed 4,311,393 adults enrolled in the JMDC Claims Database (previously known as the Japan Medical Data Center database), a nationwide epidemiologic database in Japan. The definitions of IgA nephropathy and inflammatory bowel disease (ulcerative colitis or Crohn disease) were based on International Classification of Diseases, 10th Revision codes. Individuals who had a history of IgA nephropathy were excluded. Study participants were categorized into two groups according to the presence of inflammatory bowel disease. Clinical outcomes were collected between January 2005 and May 2022. The primary outcome was incident IgA nephropathy. Results: Median (interquartile range) age was 44 (36–53) years, and 2,497,313 (58%) were men. Inflammatory bowel disease was observed in 18,623 individuals (0.4%). Over a median follow-up of 1089 (532–1797) days, there were 2631 incidences of IgA nephropathy and 22 incidences in individuals without and with inflammatory bowel disease, yielding incident ratios with 95% confidence intervals of 1.74 (1.68–1.81) and 3.43 (2.26–5.21), respectively. Kaplan–Meier curves and the log-rank test showed that a cumulative incidence of IgA was higher in individuals with inflammatory bowel disease compared with those without (log-rank P = 0.0028). Multivariable Cox regression analysis demonstrated that individuals with inflammatory bowel disease were at higher risk of incident IgA nephropathy (hazard ratio, 1.96; 95% confidence interval, 1.29 to 2.99). Conclusions: We demonstrated the potential association of inflammatory bowel disease with higher risk of developing IgA nephropathy in a general population.
A 70-year-old woman with end-stage renal disease caused by a polycystic kidney disease developed massive right-sided pleural effusion 10 days after the initiation of peritoneal dialysis (PD). Although pleuroperitoneal communication (PPC) was suspected, computed tomographic peritoneography on usual breath holding did not show leakage. Therefore, we instructed her to strain with maximal breathing, which caused a jet of contrast material to stream from the peritoneal cavity into the right pleural cavity and allowed the identification of the exact site of the diaphragm defect. Following the thoracoscopic closure of the defect, she was discharged without recurrence of hydrothorax on PD. Hydrothorax due to PPC is a rare complication of PD. Notably, numerous previous modalities used to diagnose PPC lack sufficient sensitivity. Thus, an approach to spread the pressure gradient between the peritoneal cavity and the pleural cavity on imaging may improve this insufficient sensitivity.
1 January 2019 in Journal of the Renin-Angiotensin-Aldosterone System
Introduction: Angiotensin-converting enzyme (ACE) inhibitors are one of the most commonly used medications for hypertension. Rarely, ACE inhibitors have the potential to cause a syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Case presentation: A 70-year-old woman with > 10 years ACE inhibitor therapy with normonatremia suddenly developed severe SIADH when she took a liquid diet in the uneventful perioperative period, with hemodynamic stability and no surgical complications. She promptly recovered from SIADH subsequent to discontinuing the ACE inhibitor therapy and changing her diet. Therefore, it was assumed that excess antidiuretic hormone secretion due to an ACE inhibitor and free water load from the liquid diet contributed to hyponatremia in our patient. Conclusion: Patients treated with an ACE inhibitor can latently experience inappropriate secretion of antidiuretic hormone, and rapidly develop severe hyponatremia together with additional factors affecting water or salt homeostasis regardless of the length of the administration duration. Clinicians should monitor serum sodium levels in such patients not only just after the initiation of ACE inhibitors but also upon the appearance of those factors.
Background: Hyperkalaemia poses a life‐threatening risk due to cardiac arrhythmias. Hyperkalaemic serum potassium (HK) levels are associated with the development of electrocardiograph (ECG) abnormalities, while the potential relationship between baseline serum potassium (BK) levels and these changes remains unclear. Methods: This retrospective cohort study involved outpatients identified with severe hyperkalaemia (serum potassium level ≥ 6.5 mEq/L). BK levels were defined as the average of the three most recent values prior to the severe hyperkalaemia episode. Hyperkalaemia‐associated ECG changes were determined by comparison with the recordings taken during normokalaemia. Results: Among 283 patients, the median age was 74 (63–82) years, with 90 patients (31.8%) being female. The median BK and HK levels were 5.0 (4.5–5.3) and 6.8 (6.6–7.1) mEq/L, respectively. The most frequent ECG changes in hyperkalaemia were peaked T waves (35.7%), followed by prolonged PR interval (12.1%), bradycardia (12.0%), widened QRS duration (7.8%), escape rhythm (7.1%), second‐ or third‐degree atrioventricular block (3.5%), and ventricular arrhythmias (0.7%). Logistic regression analyses adjusted for potential confounders demonstrated that both the below‐median BK and above‐median HK levels were associated with an increased likelihood of developing ECG changes (odds ratio [OR], 4.61; 95% confidence interval [CI], 2.44–8.72 and OR, 2.28; 95% CI, 1.34–3.89, respectively), as was a greater BK–HK level difference (OR, 6.85; 95% CI, 3.68–12.77). Conclusion: BK levels as well as HK levels were significant predictors of ECG abnormalities. Healthcare professionals should place emphasis on the magnitude of potassium increase when managing hyperkalaemia.
19 January 2019 in Clinical and Experimental Nephrology